posted on 2022-12-01, 15:33authored byLong Wang, Xindong Shui, Mi Zhang, Yingxue Mei, Yongfang Xia, Guihua Lan, Li Hu, Chen-Ling Gan, Yuan Tian, Ruomeng Li, Xi Gu, Tao Zhang, Dongmei Chen, Tae Ho Lee
Dysregulation of microRNAs has been implicated in diverse
diseases,
including Alzheimer’s disease (AD). MiR-191-5p in plasma/serum
has been identified as a novel and promising noninvasive diagnostic
biomarker for AD. However, whether miR-191-5p is involved in AD pathogenesis
is largely unknown, and its levels in human AD brains are undetermined.
Herein, we demonstrated that miR-191-5p downregulated tau phosphorylation
at multiple AD-related sites and promoted neurite outgrowth using
immunoblotting, immunofluorescence, and neurite outgrowth assays.
Moreover, immunoblotting and enzyme-linked immunosorbent assays indicated
that miR-191-5p decreased amyloid precursor protein phosphorylation
levels and beta-amyloid (Aβ) generation. Furthermore, miR-191-5p
reduced ceramide-induced neuronal cell death analyzed by trypan blue
staining, the in situ cell death detection kit, and Annexin V-FITC/PI
flow cytometry. Next, we verified that death-associated protein kinase
1 (DAPK1) was a direct target of miR-191-5p through the dual luciferase
reporter assay and confirmed that the effects of miR-191-5p were antagonized
by restoration of DAPK1 expression. Finally, the hippocampal miR-191-5p
level was found to be decreased in humans with AD compared with controls
and was inversely correlated with the DAPK1 expression level. Collectively,
these findings suggest that miR-191-5p might exert inhibitory effects
on tau phosphorylation, Aβ secretion, and neuronal cell death
by directly targeting DAPK1, providing an attractive therapeutic option
for AD.